Macrogenics Inc Stock Price, News & Analysis

On September 12, 2021, MacroGenics (Nasdaq: MGNX) announced multiple poster presentations for its investigational product candidates at the ESMO Virtual Conference scheduled for September 16-21, 2021. Key presentations include preliminary results for MGC018, an antibody-drug conjugate targeting advanced solid tumors, and data from the MAHOGANY trial on margetuximab in HER2+, PD-L1+ gastroesophageal adenocarcinoma. The posters will be accessible on the ESMO website and MacroGenics' investor relations page.

MacroGenics announced the final overall survival (OS) results of the SOPHIA Phase 3 study for MARGENZA (margetuximab-cmkb) in HER2-positive metastatic breast cancer. The study showed no statistically significant OS advantage for MARGENZA plus chemotherapy (21.6 months) compared to trastuzumab plus chemotherapy (21.9 months; HR=0.95, P=0.62). However, a subgroup analysis indicated improved OS in patients with the CD16A 158F allele. Safety profiles were consistent with prior reports. Further studies are planned to explore MARGENZA's effects based on CD16A variants.

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company, announced its participation in several investor conferences in September 2021. The events include Citi’s 16th Annual BioPharma Virtual Conference on September 9, featuring a panel discussion on oncology therapies. Additionally, MacroGenics will engage in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15 and another at the 2021 Cantor Virtual Global Healthcare Conference on September 30.

Webcasts of these presentations will be available on the company's investor relations website.

MacroGenics, Inc. (Nasdaq: MGNX) announced its participation in two key conferences in August 2021. The first event is the BTIG Virtual Biotechnology Conference on August 10, where management will engage in a fireside chat at 9:30 am ET and conduct one-on-one meetings. The second is the 12th Annual Wedbush PacGrow Healthcare Conference on August 11, featuring CEO Scott Koenig in a panel discussion titled ADCs – Take Me to Your Tumor at 2:20 pm ET, along with one-on-one meetings. Webcast access for these events is available on their website.

MacroGenics, Inc. (NASDAQ: MGNX) reported its Q2 2021 financial results, highlighting a revenue increase to $30.8 million, up from $20.3 million in Q2 2020, driven by collaborations and MARGENZA sales. The company is progressing with its clinical pipeline, including upcoming data presentations at ESMO. Key financials include a net loss of $39.9 million and total cash and equivalents of $297.3 million as of June 30, 2021. Guidance indicates funding through 2023, contingent on program advancements.

MacroGenics, a biopharmaceutical company focused on monoclonal antibody therapeutics for cancer, will release its financial results for Q2 2021 on July 29, 2021, after market close. A conference call to discuss these results and corporate progress will be held the same day at 4:30 PM ET. Interested parties can access the call by dialing (877) 303-6253 for domestic calls or (973) 409-9610 for international calls. The call will also be available via a webcast on the company's investor relations page.

MacroGenics (NASDAQ: MGNX) has announced a significant collaboration with Zai Lab, granting exclusive rights to develop up to four bispecific molecules targeting immuno-oncology. The deal includes an upfront payment of $25 million and a $30 million equity investment in MacroGenics at $31.30 per share. The collaboration allows both companies to leverage their intellectual properties, with Zai receiving rights in Greater China, Japan, and Korea, and MacroGenics retaining rights in other territories. Potential milestone payments could total $1.4 billion, along with royalties from net sales.

MacroGenics (NASDAQ: MGNX) reported encouraging preliminary data from its Phase 1 trial of MGC018, an investigational anti-B7-H3 antibody-drug conjugate. Preliminary results show anti-tumor activity in melanoma and metastatic castration-resistant prostate cancer (mCRPC), with 50% of mCRPC patients achieving a significant PSA reduction. The trial enrolled 29 patients, with a recommended Phase 2 dose established at 3.0 mg/kg. A conference call to discuss the results is scheduled for June 4, 2021, coinciding with a presentation at the ASCO Annual Meeting.

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company, announced its participation in Cowen’s 2nd Annual Virtual Oncology Innovation Summit. The management will engage in a fireside chat on May 20, 2021, at 9:20 am ET. A webcast of the event can be accessed on the Company’s Investor Relations page. MacroGenics focuses on developing monoclonal antibody-based therapeutics for cancer treatment, leveraging innovative technology platforms and strategic collaborations for its product pipeline.